Full Fed. Circ. Should Nix UCB's Vimpat Patent, Accord Says
Generic-drug makers Accord Healthcare Inc. and Intas Pharmaceuticals Ltd. on Thursday urged the full Federal Circuit to consider invalidating a UCB Inc. patent covering the epilepsy drug Vimpat, arguing that the...To view the full article, register now.
Already a subscriber? Click here to view full article